BioCentury | Feb 1, 2020
Company News

BioNTech’s approach to matching technologies to tumors

...which uses mRNA to encode therapeutic mAbs that are secreted in vivo . Two programs, BNT141...
BioCentury | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies bring two RNA-encoded antibody candidates from its “RiboMab” platform to the clinic in 2H20. BNT141...
Items per page:
1 - 2 of 2